SEC Form 4 · accession 0001209191-17-042169
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mardi Dier
Officer — Executive VP and CFO
Period of report
Jun 27, 2017
Accepted (ET)
Jun 28, 2017 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 27, 2017 | M | 8,350 | $7.00 | A | 8,350 | D | |
| Common StockF1 | Jun 27, 2017 | M | 1,191 | $7.00 | A | 1,191 | D | |
| Common StockF1 | Jun 27, 2017 | M | 16,029 | $9.50 | A | 16,029 | D | |
| Common StockF1 | Jun 27, 2017 | M | 60,937 | $22.06 | A | 60,937 | D | |
| Common StockF1 | Jun 27, 2017 | M | 6,885 | $25.08 | A | 6,885 | D | |
| Common StockF2,F1 | Jun 27, 2017 | S | 42,421 | $54.94 | D | 50,971 | D | |
| Common StockF3,F1 | Jun 27, 2017 | S | 46,478 | $55.83 | D | 4,493 | D | |
| Common StockF4,F1 | Jun 27, 2017 | S | 4,493 | $56.61 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.00 | Jun 27, 2017 | M | 8,350 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 8,350 | 0 | D |
| Stock Option (Right to Buy)F1 | $7.00 | Jun 27, 2017 | M | 1,191 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 1,191 | 0 | D |
| Stock Option (Right to Buy)F1 | $9.50 | Jun 27, 2017 | M | 16,029 | D | Dec 13, 2012 | Dec 13, 2022 | Common Stock | 16,029 | 0 | D |
| Stock Option (Right to Buy)F1 | $22.06 | Jun 27, 2017 | M | 60,937 | D | Nov 6, 2013 | Nov 6, 2023 | Common Stock | 60,937 | 6,250 | D |
| Stock Option (Right to Buy)F1 | $25.08 | Jun 27, 2017 | M | 6,885 | D | Mar 26, 2014 | Mar 26, 2024 | Common Stock | 6,885 | 57,177 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.41 to $55.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.41 to $56.40, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.43 to $56.92, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) to this Form 4.